The FDA approved niraparib with abiraterone acetate and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer based on the AMPLITUDE trial results. The trial demonstrated ...

Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...

The ProVee System received FDA approval for treating BPH, offering a safe and effective procedure for symptom relief and quality of life improvement. The ProVIDE study showed significant improvement ...

The ASPIRE trial evaluates the addition of docetaxel to standard hormone therapy and apalutamide in metastatic castration-sensitive prostate cancer. Approximately 1200 participants will be enrolled ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...

Neuspera's iSNM system provides a battery-free alternative to traditional SNM, reducing complications and surgeries for UUI patients. The SANS-UUI trial showed 84.2% of patients achieved at least a 50 ...

BCG plus mitomycin demonstrated similar efficacy and safety to BCG alone, with fewer treatment discontinuations and reduced BCG doses in NMIBC patients. The combination therapy showed a 40% reduction ...

The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices. Michael S. Cookson, MD, and Jason M.

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

The proposed budget cut reduces CDMRP funding from $1.509 billion in FY2024 to $650 million in FY2025, affecting cancer research funding. Organizations like Zero Prostate Cancer and the American ...

Testosterone replacement therapy may not increase prostate cancer recurrence risk, but evidence remains inconclusive, necessitating individualized treatment plans. Bipolar androgen therapy (BAT) ...

"This study provides a comprehensive review of the role of natural products as complementary treatments for prostate cancer," says Channing J. Paller, MD. In this video, Channing J. Paller, MD, gives ...